MedinCell Announces the Availability of its 2021/2022 Universal Registration Document Including the Annual Financial Report
29 Julho 2022 - 01:30PM
Business Wire
Regulatory News:
MedinCell (FR0004065605 - MEDCL) (Paris:MEDCL), a
pharmaceutical company at premarketing stage developing a portfolio
of long-acting injectable products in various therapeutic areas,
announces today the filing of its 2021/2022 Universal Registration
Document (URD) with the French market authority (Autorités des
Marchés Financiers, or AMF) under the reference D.22-0662.
The universal registration document notably includes:
- the annual financial report for the year ending on March 31,
2022;
- the management report;
- the CSR report;
- the report on corporate governance; and
- the proposed text of the resolutions to be submitted to the
ordinary and extraordinary Shareholders' Meeting of September 8,
2022.
This universal registration document may be consulted on the
Company’s website (invest.medincell.com), “Investors” section, and
on the AMF’s website (www.amf-france.org).
About MedinCell
MedinCell is a pharmaceutical company at premarketing stage that
develops a portfolio of long-acting injectable products in various
therapeutic areas by combining its proprietary BEPO® technology
with active ingredients already known and marketed. Through the
controlled and extended release of the active pharmaceutical
ingredient, MedinCell makes medical treatments more efficient,
particularly thanks to improved compliance, i.e. compliance with
medical prescriptions, and to a significant reduction in the
quantity of medication required as part of a one-off or chronic
treatment. The BEPO® technology makes it possible to control and
guarantee the regular delivery of a drug at the optimal therapeutic
dose for several days, weeks or months starting from the
subcutaneous or local injection of a simple deposit of a few
millimeters, fully bioresorbable. MedinCell collaborate with tier
one pharmaceuticals companies and foundations to improve Global
Health through new therapeutic options. Based in Montpellier,
MedinCell currently employs more than 140 people representing over
25 different nationalities.
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220729005429/en/
MedinCell David Heuzé Head of communication
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Mathilde Bohin / Louis-Victor Delouvrier Relations
investisseurs medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations medincell@newcap.eu +33
(0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024